Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MRS 2578 是一种选择性强的P2Y6 受体拮抗剂,IC50为 37 nM,对 P2Y1、P2Y2、P2Y4 和 P2Y11 受体显示出不显着的抑制作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 320 | 现货 | ||
10 mg | ¥ 430 | 现货 | ||
25 mg | ¥ 846 | 现货 | ||
50 mg | ¥ 1,638 | 现货 | ||
100 mg | ¥ 2,448 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 333 | 现货 |
产品描述 | MRS2578, an effective P2Y6 receptor antagonist with IC50 of 37 nM, shows insignificant inhibition at P2Y1, P2Y2, P2Y4, and P2Y11 receptors. |
靶点活性 | P2Y6:37 nM |
体外活性 | MRS2578 selectively blocks P2Y6 receptor activity versus activity at P2Y1, P2Y2, P2Y4 or P2Y11 receptors. MRS2578 (1 μM) completely blocks the protection by UDP undergoing TNFalpha-induced apoptosis in 1321N1 astrocytoma cells. [1] MRS 2578 inhibits basal NF-κB activity in time and dose dependent manner in HMEC-1 cells transfected with 0.25 μg NF-κB promoter reporter. MRS 2578 (10 μM) completely abolishes TNF-α induced NF-κB reporter activity in HMEC-1 cells. MRS 2578 (10 μM) significant reduces TNF-α–induced proinflammatory gene expression in HMEC-1 cells. [2] MRS 2578 potentiates ATPγS and UDP response at concentrations below 316 nM whereas above this concentration, MRS 2578 inhibits ATPS- and UDP-induced IP accumulation in neonatal rat cardiac myofibroblasts. [3] MRS2578-treated mice shows reduced bronchial hyperresponsiveness toward methacholine in OVA-sensitized mice. MRS2578 completely blocks UDP-induced the release of IL-6, KC, and IL-8 in lung epithelial cells. [4] |
体内活性 | MRS 2578 (10 μM) attenuates Keratinocyte-derived chemokine serum protein levels in LPS-induced vascular inflammation in C57BL/6 mice. [2] MRS2578 (10 μM, intratracheally) reduces BALF eosinophilia and the levels of IL-5 and IL-13 in the BALF in OVA-sensitized mice and leads to a markedly attenuated change in methacholine responsiveness after OVA challenge. MRS2578 (10 μM, intratracheally) inhibits house dust mite–induced allergic airway inflammation in OVA-sensitized mice. MRS2578 (10 μM, intratracheally) reduces of IL-6 and KC levels in BALF in OVA-sensitized mice. [4] |
分子量 | 472.67 |
分子式 | C20H20N6S4 |
CAS No. | 711019-86-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 23.6 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1156 mL | 10.5782 mL | 21.1564 mL | 52.891 mL |
5 mM | 0.4231 mL | 2.1156 mL | 4.2313 mL | 10.5782 mL | |
10 mM | 0.2116 mL | 1.0578 mL | 2.1156 mL | 5.2891 mL | |
20 mM | 0.1058 mL | 0.5289 mL | 1.0578 mL | 2.6446 mL | |
50 mM | 0.0423 mL | 0.2116 mL | 0.4231 mL | 1.0578 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MRS 2578 711019-86-2 Apoptosis GPCR/G Protein Neuroscience P2Y Receptor inhibit MRS-2578 MRS2578 Inhibitor inhibitor